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The prognosis of pancreatic adenocarcinoma is affected by early metastases and local tumour invasion beyond surgical margins. Gene
expression profiling in pancreatic cancer tissue is complicated due to the high amount of RNAses being present in human tissue and
that of suitable models. In order to demonstrate early metastases, the models should take into account the anatomical environment
of the tumour. Using the orthotopic transplantation of pancreatic tumour cells in SCID (severe combined immunodeficiency) mice,
these interactions are taken into consideration. In order to identify genes associated with local tumour invasion and metastases in
ductal pancreatic cancer, we investigated a human pancreatic tumour cell line derived from an orthopic pancreatic tumour model in
SCID mice. Differential gene expression was performed on the basis of microarray technique. The human MiaPaca-2 cell line was
implanted orthotopically in SCID mice. Transcriptional profiling was performed on fresh frozen tissue derived from the primary
tumour, the tumour invasion front and the liver metastases. Differentially expressed genes were identified using statistical analyses,
and were validated with external databases and with immunohistochemistry. A total of 1066 of 14500 genes were significantly
differentially expressed. Comparing the primary tumour with the tumour invasion front, there were 614 statistically significant up- and
348 downregulated genes. Twenty-five statistically significant up- and 181 downregulated genes were identified comparing the liver
metastases with the primary tumour. Eight genes (PAI-1, BNIP3l, VEGF, NSE, RGS4, HSP27, GADD45A, PTPN14) were chosen and
validated in a semi-quantitative immunohistochemical analysis, which revealed a positive correlation to the array data.
Overrepresentation analyses revealed a total of 66 significantly regulated pathways associated with cell proliferation, cell stress,
cell communication metabolic and cytokine function. In conclusion, model marker genes for local invasion and liver metastases can be
identified using transcriptional profiling in the SCID mouse. Overrepresentation analysis secures a good and fast overview about the
significantly regulated genes and can assign genes to certain pathways. These marker genes can be related to the apoptotic cascade,
angiogenesis and cell interaction.
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Although the treatment of various types of cancer has improved
over the past few years, the prognosis of pancreatic ductal
adenocarcinoma (PDAC) remains poor. Pancreatic cancer is the
fifth leading cause of cancer deaths in the United States (Jemal
et al, 2003), and shows a 5-year survival rate of less than 5%. The
poor prognosis can be explained by high rate of local recurrences
and distant metastases after surgery, as well as frequent diagnosis
being made at late stages of disease. This limits the role of surgery
as a curative modality. Despite all modern diagnostic tools early
detection of PDAC, even in an extended disease has been difficult
up to now (Eskelinen and Haglund, 1999). Furthermore, lymphatic
or distant metastases as well as unknown tumour infiltration into
large vessels is frequently observed in potentially curative
resections (Hartel et al, 2002; Richter et al, 2003), further limiting
the surgical therapeutic options (Trede et al, 2001). In the past few
years, a number of cancer-related genes could be identified in
pancreatic cancer, the most common of which are K-ras, DPC4,
p53 and p16 (Almoguera et al, 1988; Hahn et al, 1996; Hruban et al,
1998; Slebos et al, 2000). However, the published array data are
limited to the differential gene expression between normal
pancreatic tissue and PDAC, and does not address important
aspects such as progression and metastasis (Pilarsky et al, 2004).
The genome is very complex and most of the molecular changes
causing pancreatic cancer are still unknown. Most importantly
there is a lack of knowledge about the molecular components of
early progression and metastases, which are two main reasons for
the overall poor prognosis. In order to reflect early metastases,
there is a demand for models representing the anatomical
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senvironment of the tumour. Using the orthotopic transplantation
of pancreatic tumour cells into SCID (severe combined immuno-
deficiency) mice, these interactions are taken into account (Alves
et al, 2001). In order to identify genes associated with local tumour
invasion and metastases in PDAC, we examined pancreatic tumour
cells derived from an orthotopic pancreatic tumour model in SCID
mice regarding their potential to establish metastases and to
infiltrate duodenum. Gene expression profiling was performed
on the basis of microarray technique. The biological functions of
the differentially expressed genes were analysed by means
of pathway analysis, and the changes of gene expression at the
level of biological pathways or co-regulated gene sets were
evaluated. Furthermore, we validated genes of this set using
immunohistochemistry in order to prove the appropriateness of
our approach.
MATERIALS AND METHODS
MiaPaca-2 cell line
The human pancreatic ductal adenocarcinoma cell line Mia PaCa-2
(established by Yunis et al, 1977) was provided by Kalthoff et al
(1993) (Kiel, Germany). The cells were cultured in RPMI 1640,
which was supplemented with penicillin (50IUml
 1), strepto-
mycin (50mgml
 1), L-glutamine (2mM) (Gibco BRL, Eggenstein,
Germany) and 10% foetal calf serum (PAN, Aidenbach, Germany),
at 371C in a humidified atmosphere of 5% CO2. The cultured cells
were gained by short trypsinisation in 0.25% trypsin–EDTA
solution (Gibco, Karlsruhe, Germany) from semiconfluent culture
dishes and washed several times. Shortly before implantation, the
cells were placed into sterile phosphate-buffered saline (PBS). In
addition the MiaPaca cells were fixed in Hank’s balanced salt
solution containing 4% formaldehyde and were processed for
paraffin embedding.
SCID mouse model
The SCID mouse model, which presents an orthotopic and
metastatic model, was established by Alves et al (2001). Severe
combined immunodeficiency mice (age 24–28 weeks; strain
C.B-17/Ztm-scid of both sexes; weight 24–26, 4g (female) and 26,
3–32, 4g (male)) were used for the tumour implantation. By
measuring serum immunoglobulin levels by Ouchterlony test and
using an enzyme-linked immunosorbent assay for immunoglobulin,
leaky SCID mice (immunoglobulin410mgml
 1) were detected
and excluded from further experiments. All animals were
maintained in a sterile environment in special cages with filter
hoods in a scantainer (Scanbur, Koge, Denmark) on a daily 12-h
light/dark cycle. Cages, bedding and water were autoclaved and the
chow was sterilised by gamma radiation. All manipulations were
conducted under aseptic conditions using a laminar flow hood. In
accordance with guidelines for animal welfare, all experiments
performed were approved by the administration of Niedersachsen
(Lower Saxony, Germany).
Tumour implantation
Under general anesthesia using a mixture of ketamine (75–100
mgkg
 1) and xylazine (15–20mgkg
 1), the orthotopic trans-
plantation was performed intraperitoneally. A median laparotomy
was performed, approximately 1cm in length, peritoneum was
opened, the pancreas was carefully exposed by applying gentle
traction to the stomach. Aliquots of 1 10
6 MiaPaca-2 cells in a
volume of 15ml PBS were injected with an insulin syringe, 29 gauge
(Becton Dickinson, Heidelberg, Germany), very slowly into the
proximal part of the pancreas. The implanted cells were visible as
an infiltration in the pancreatic tissue. The needle was slowly
withdrawn after 1min. After returning the pancreas to the
abdominal cavity, the incision was closed in two layers using a
continuous Vicryl suture (Metric 1.5; Ethicon, Norderstedt,
Germany) for the peritoneum and an interrupted suture for the
skin. The procedure was tolerated well by all the animals. After the
implantation, the mice were inspected daily for body weight
loss, general condition and tumour formation in the peritoneal
cavity.
Termination of the trial
In case of a rapid tumour progression, the trial was terminated
(usually 39–60 days) and the general condition of the animals
(defined in terms of the condition of the coat, nutrition and
behaviour) was assessed daily. The mice were killed after an
average of 56 days. Autopsies were performed and the abdominal
and the thoracic cavities were examined systematically for the
presence of metastases. All findings and complications, such as
ascites, level of invasion into the surrounding tissue, the size,
number and the location of tumours were recorded. The pancreatic
tumour mass, including the attached organs, metastases, suspi-
cious nodular formations, lung, liver, spleen, kidneys, adrenal
glands, diaphragm, various parts of the intestine, bladder and male
and female reproductive organs were excised, placed in phosphate-
buffered 4% formalin for 16h at room temperature and embedded
in paraffin. In addition, three different specimens from the
primary tumour, the tumour invasion front and the liver
metastases were dissected, snap frozen and stored at  801C for
further analyses.
RNA preparation and array hybridisation
The RNA was isolated using TRIZOL-Reagent (Invitrogen,
Carlsbad, CA, USA). After measuring the concentration of RNA
and approving for purity by Agilent Bioanalyzer 2100, the
RNA was transferred into cDNA using Superscript II (Invitrogen,
Carlsbad, CA, USA). In a second step, the cDNA was treated
by RNA-transcript-labelling kit (Enzo Diagnostics, Farmingdale,
NY, USA) in order to obtain biotin-labelled RNA. Hybridisation
and detection of the labelled RNA on the U133 Affymetrix
GeneChip were performed according to the instructions of
Affymetrix.
Design of the chip experiment and the bioinformatical
analysis
Gene expression profiling was performed using arrays of HG-
U133A type from Affymetrix. The 22000 probe sets represent
18400 transcripts and 14500 genes. In total nine arrays, three
containing primary tumour material, three containing material of
the tumour invasion front and three containing liver metastases
material were hybridised. Only probe sets unique to single
transcripts with the Affymetrix extension _at, or those unique to
common parts among transcripts from the same gene with
extension _s_at were taken into consideration. Differential gene
expression was analysed based on loglinear mixed model ANOVA
(Hsieh et al, 2003; Roy, 2007), using a commercial software
package Micro Array Solution, version 1.0, from SAS (SAS
Institute, Cary, NC, USA). The experimental group and probe
were considered to be with fixed effects and the chipid random.
A false positive rate of a¼0.05 with Bonferroni correction
(according to a P-value slightly smaller than 0.000001) was taken
as the level of significance. The results were presented in lists of
significantly regulated genes. The three different types of tissue,
the primary tumour, the tumour invasion front and the liver
metastases, were compared with each other.
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The overrepresentation analysis (ORA) is a microarray data
analysis that uses predefined gene sets to identify a significant
overrepresentation of genes in data sets (Subramanian et al, 2005;
Manoli et al, 2006). Pathways belonging to various cell functions
such as cell cycle or apoptosis were obtained from public external
databases (KEGG: www.kegg.com, Superarray: www.superarray.com).
A Fisher’s exact test was performed to detect the significantly
regulated pathways.
Immunohistochemical staining
Based on the list of significantly regulated genes (Table 1), we
selected the following eight genes for further immunohisto-
chemical validation: BNIP3L, regulator of G protein signalling 4
(RGS4), plasminogen activator inhibitor 1 (PAI-1), GADD45A,
PTPN14, vascular endothelial growth factor (VEGF), neuron-
specific enolase (NSE) and HSP27. Sections of formalin-fixed,
paraffin-embedded tumour tissue with a thickness of 3mm were
deparaffinised and dehydrated. The slides were pretreated in a
microwave (900W/15min in citrate buffer at pH 6.0) and were
treated for 5min with hydrogen peroxide (3% hydrogen peroxide
in methanol). They were then blocked with non-diluted serum for
30min. Goat serum was used for PAI-1, GADD45A, PTPN14,
VEGF, NSE and HSP27. For RGS4 staining we used rabbit serum.
For the liver metastases specimen, we employed the avidin–biotin
blockade due to the high amount of biotin being present. The
primary antibodies were incubated at 41C overnight. In order to
stain the BNIP3L protein, we administered rabbit polyclonal
anti-BNIP3L antibodies (dilution: 1:100, Abcam plc, Cambridge,
England), and for the RGS4 we chose goat polyclonal anti-RGS4
antibodies (dilution 1:400, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). K 562 cells were used as positive control for the
BNIP3l antibody, and human brain tissue was used as positive
control for the RGS4 antibody. Anti-PAI-1 antibodies are rabbit
polyclonal antibodies (Abcam plc, Cambridge, England), and these
were administered at a 1:50 dilution. Breast tissues, normal tissues
and cancer tissues were used as positive control. We used the
rabbit polyclonal anti-GADD45A antibodies at a 1:500 dilution
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); the K 562
cells served as positive control. PTPN14 was detected with chicken
polyclonal anti-PTPN14 antibodies (1:300; Biomol GmbH, Hamburg,
Germany). As positive control we used pancreatic and breast
tissue. The VEGF protein was stained with goat-polyclonal anti-
VEGF antibodies (1:300, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA). Vein tissue was used as positive control. For NSE
staining we chose rabbit polyclonal anti-NSE antibodies (1:300;
Abcam plc, Cambridge, England) and pancreas tissue as positive
control. And finally, for the protein HSP27 we selected rabbit
polyclonal anti-HSP27 antibodies (1:250; Abcam plc, Cambridge,
England). As positive control we stained breast and cervix normal
and cancer tissues. The secondary antibodies were applied with
polyclonal anti-rabbit antibodies, except for RGS4 and PTPN14
staining. For the latter two we used anti-goat and anti-chicken
antibodies (Vector Laboratories Ltd., Peterborough, England) for
30min at room temperature. All immunostainings were performed
for 30min at room temperature using the streptavidin–biotin
method (Vector Laboratories Ltd., Peterborough, England). The
stainings were detected by 3,3 ´-diaminobenzidine. For the PAI-1
staining, however, we applied the NovaRed method (Vector
Laboratories Ltd., Peterborough, England). The slides were
counterstained with Mayer’s haematoxylin.
Evaluation of protein expression
Semi-quantitative assessment of the immunhistochemistry
staining was based on scoring the number of all positive cells
per 200 field, including carcinoma/metastasis/invasion front,
and stromal cells (fibroblasts, macrophages, endothelial cells and
lymphocytes). Normal pancreatic parenchyma was also screened
for the presence of protein expression in acinar, ductal and
endocrine cells. The tumour cell density was similar in all samples.
In each slide three fields were evaluated. If there was no staining
observed, the case was scored as ‘0’. If the tumour tissue consisted
of less than 10% immunoreactive cells, the case was rated as ‘1’
(weak), while cases with 10–50% immunoreactive cells were
scored as ‘2’ (moderate) and those with more than 50%
immunoreactive cells were scored as ‘3’ (strong). The semi-
quantitative assessment of all parameters was performed by two
independent observers (Niedergethmann (M) and Neff (JK)).
RESULTS
Bioinformatical analysis
The array-based gene expression analysis revealed a total of
1066 statistically significant differentially expressed genes
(P-valuep10
 6.13). Comparing the gene expression profile of the
primary tumour with the tumour invasion, there were 614 genes
upregulated and 348 genes downregulated. In comparison to the
primary tumour, there were 25 genes overexpressed and 181 genes
underexpressed in the liver metastases. Furthermore, we found 73
genes upregulated and 37 genes downregulated comparing liver
metastases with tumour invasion front. We noted a homogenous
distribution of significantly regulated genes in all specimens. We
selected eight significantly regulated genes based on their high
P-value and a greater log2 fold change (41). In liver metastases
and the tumour invasion front, these genes revealed a statistically
significant downregulation compared with the primary tumour.
We compared these genes with the data from the current literature:
BNIP3L, RGS4, PAI-1, GADD45A, PTPN14, VEGF, NSE and HSP27
(Table 1). Based on the comparison with external databases and
using immunohistochemistry, the differential expression of these
genes was validated.
Table 1 Panel of possible marker genes for local tumour invasion and liver metastases in pancreatic carcinoma: function and statistical significance
Gene symbol Localisation Description Function P-value (Po10
 x)
RGS 4 LM/IF Regulator of G-protein signalling 4 Signal transduction 23.669
Serpine (PAI) LM/IF Serine (or cysteine) proteinase inhibitor Cell migration 23.555
GADD45A LM/IF Growth arrest and DNA-damage-inducible, alpha Apoptosis, cell migration 19.428
BNIP3L LM/IF BCL2/adenovirus E1B 19kDa interacting Apoptosis 11.348
PTPN14 LM/IF Protein tyrosine phosphatase, non-receptor type 14 Amino-acid dephosphorylation 10.808
VEGF LM/IF Vascular endothelial growth factor Angiogenesis, cell migration, apoptosis 9.004
ENO2 (NSE) IF Enolase 2 (gamma, neuronal) Glycolysis 8.463
HSPB1 (HSP27) IF Heat-shock 27-kDa protein 1 Glycolysis 7.163
IF¼invasion front; LM¼liver metastases; NSE¼neuron-specific enolase.
Gene expression profiling in pancreatic cancer
M Niedergethmann et al
1434
British Journal of Cancer (2007) 97(10), 1432–1440 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sPathway analysis
The ORA revealed a total of 66 significantly regulated pathways.
The comparison of the primary tumour with the tumour invasion
front showed 30 significantly regulated pathways. The comparison
of the metastases with the tumour invasion front demonstrated 13
and that of the metastases with the primary tumour revealed 23
significantly regulated pathways. In Table 2 all pathways, which
could be associated with important cell interactions in pancreatic
cancer are summarised. Pathways linking the primary tumour with
the tumour invasion front or with the liver metastases are mainly
involved in cell proliferation, cell stress and cell communication.
Pathways between primary tumour and tumour invasion front are
associated with cytokine function. Those linking primary tumour
with liver metastases are metabolic pathways.
Comparison with published data
In order to interpret our results in a general context, we analysed
data that have already been published on this topic over the past
few years (Han et al, 2002; Iacobuzio-Donahue et al, 2003a;
Gru ¨tzmann et al, 2004). We found that 75 of our genes had already
been reported by other institutions, which analysed PDAC with
microarrays. For clarity, only those genes with P-values lower
than 10
 6.13 are presented in Table 3. Regarding the significantly
regulated pathways, however, we found out that only those
involved in cell proliferation, cell stress and cell communication
have already been described before (Gru ¨tzmann et al, 2004;
Table 2, section A), whereas those being associated with cytokine
or metabolic function (Table 2, sections B and C) have not been
described yet.
Immunohistochemical staining
For all genes selected, the differential expression of the resulting
protein could be confirmed by immunohistochemical staining. For
all chosen genes downregulated in liver metastases and invasion
front in comparison to the primary tumour, such as VEGF, BNIP3l
and HSP27, we found a stronger cytoplasmatic and nuclear
immunoreactivity in the primary tumour in comparison with
liver metastases/tumour invasion front (examples shown in
Figures 1–3). (All protein stainings are detected in cancer cells.
Vascular endothelial growth factor staining was also observed in
endothelial cells. Antibodies to proteins such as VEGF, PAI-1,
HSP27, NSE, PTPN14 and BNIP3L showed a strong immuno-
reactivity in our study.) The immunoreactivity of the BNIP3L and
PTPN14 staining was strong in the primary tumour (score 3),
whereas weak staining was observed in the liver metastases (score
1). The immunohistochemical staining of GADD45A and RGS4 was
weak in all localisations. The results of array data in comparison to
immunohistochemistry scoring are represented in Table 4 and in
Figures 1–3.
DISCUSSION
Since the establishment of the human genome project, sequence
information of the entire human genome has become available.
The human genome can be used for global analyses of gene
expression in the form of DNA microarrays. Over the past few
years, gene expression profiling has been applied to a number of
tumours such as breast, colon, prostate, oesophagus and stomach
tumours (Gru ¨tzmann et al, 2004). Several studies using different
methods have elucidated gene expression changes in PDAC
(Iacobuzio-Donahue et al, 2003a; Gru ¨tzmann et al, 2004). The
use of an orthotopic animal model has recently been described by
Nakamura et al (2007) as an appropriate method of reflecting the
metastasising cascade of tumours in human beings. The purpose of
this study was to identify genes associated with metastases and/or
local tumour invasion in PDAC. Tumour lesions could easily be
obtained even in cases of liver metastases or the tumour invasion
front. Therefore a microdissection was not necessary in our model.
Using the well-established SCID mouse model we could gain a
good quality of RNA from the primary tumour, the tumour
invasion site and the liver metastases.
Table 2 Panel of significantly regulated pathways revealed by ORA: pathways in section A are significantly regulated in both primary tumour to tumour
invasion front and primary tumour to liver metastases
Section Significant pathways Primary tumour vs tumour invasion Primary tumour vs liver metastases
A cosmic cancer
a
ecr_adhesionmolecules
b
nitricoxide
b
tgfb_signalingpathway
b
tryptophan_metabolism
c
wnt_signalling_pathway
b
B chemokine_receptor_family
b
pdgf_family
c
commoncytokine
b
growthfactor
b
inflammatorycytokines_recm
b
C apoptosis_bcl2_apaf_casp
c
arginine_and_proline_metabolism
c
beta_alanine_metabolism
c
Biosynthesis_of_steroids
c
glycosaminoglycan_degradation
c
krebs_tca_cycle
c
mapk_activ_transcr_factor
c
methionine_metabolism
c
pyruvate_metabolism
c
mapk¼mitogen-activated protein kinase; ORA¼overrepresentation analysis; tgfb¼transforming growth factor b. They are mainly involved in cell proliferation, cell stress and
cell communication. Pathways in section B are only significantly regulated in the link between primary tumour to tumour invasion front, and are associated with cytokine function.
All pathways in section C are metabolic pathways playing an important role when comparing primary tumour and liver metastases.
awww.sanger.ak.uk.
bwww.superarray.com.
cwww.kegg.com.
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significantly differentially regulated genes. Comparing the tissue
from the primary tumour with the tumour invasion front, we
observed 614 upregulated and 348 downregulated genes. Twenty-
five upregulated genes and 181 downregulated genes could be
identified comparing the metastases with the primary tumour. A
comparison of the metastases with the tumour invasion revealed
73 upregulated and 37 downregulated genes. Remarkably, we could
find less upregulated genes in the liver metastases than in the
primary tumour, indicating a possible loss of regulating and
tumour suppressor genes. The same observation has been made by
other groups (Li et al, 2004; Zucchi et al, 2004). Zucchi et al (2004)
hypothesised that the downregulation of a set of genes may be the
basic mechanism of cancer formation, whereas the upregulation
may characterise and possibly control the state of evolution of
individual cancers.
A number of these genes have already been reported by other
authors. We noticed that 75 genes that have already been reported
were also significantly regulated in our study (Han et al, 2002;
Iacobuzio-Donahue et al, 2003a; Gru ¨tzmann et al, 2004; Table 3).
However, we found additional genes that have not yet been found
to be differentially expressed in pancreatic cancer, but have been
identified within other malignancies. The largest numbers of the
significantly regulated genes are those that have not yet been
associated with any type of carcinoma. Furthermore, using our
metastasising model we could describe for the first time genes such
as PAI-1 (SERPINE 1) and HSP27 showing a downregulation in the
liver metastases as well as in the tumour invasion front (Tables 1
and 4).
In order to define the biological function of the genes and for
purposes of validation, we analysed the changes in the gene
expression at the level of biological pathways or co-regulated gene
sets. Overrepresentation analysis is one way of handling the large
amount of data and obtaining an adequate and efficient overview
of a microarray data set, which in turn allows to obtain biologically
valid data. Using the ORA we observed 30 significant pathways
comparing the primary tumour with the tumour invasion front, 13
pathways comparing the liver metastases with the tumour invasion
front and 23 pathways comparing the primary tumour with liver
metastases. We summarised relevant pathways for pancreatic
cancer and assigned them to certain cell functions (such as cell
proliferation) (Table 2). In pancreatic cancer pathways playing a
role in cell proliferation, cell stress and cell communication have
already being described before (Gru ¨tzmann et al, 2004). Using our
metastasising model, we could detect specific pathways being
possibly linked with liver metastases or the local tumour invasion
front. Those, which might be associated with liver metastases are
mainly involved in metabolic function and reflect the scope of liver
synthesis. On the other hand, those, which might be linked with
the tumour invasion front consist of cytokine function and
therefore present the typical pancreatic cancer peritumoral
inflammation. This implicates further cross-validation and con-
firmation with for instance intraoperatively extracted tissue in a
series with patient specimen.
For all three tissue specimen, only the so-called Cosmic Cancer
and the tgf-beta-signalling pathway were significantly expressed.
In the Cosmic Cancer pathway, multiple somatic mutations in
cancers are comprised based on a study by Futreal et al (2004).
Table 3 Overview of differentially expressed genes (P-valueo10
 x) with gene symbols, P-values and references concerning differential expression in
previous expression profiling experiments in PDAC
P-value (10
-x)
Gene
Gene
symbol
Primary tumour vs
tumour invasion
Liver metastases vs
tumour invasion
Primary tumour vs
liver metastasess
Reference
in PDAC
Lanyl (membrane) aminopeptidase (aminopeptidase N,
aminopeptidase M, microsomal aminopeptidase, CD13, p150)
ANPEP 6.614 1.563 2.4793 1a
Actin-related protein 2/3 complex, subunit 5, 16kDa ARPC5 11.620 3.033 4.407 1a
BCL2/adenovirus E1B 19kDa interacting protein 3 BNIP3L 13.809 0.273 11.348 1c
Cyclin B1 CCNB1 1.969 11.065 6.669 1b
CD24 antigen (small-cell lung carcinoma cluster 4 antigen) CD24 6.688 3.206 0.967 1a, 1c
Cartilage oligomeric matrix protein (pseudoachondroplasia,
epiphyseal dysplasia 1, multiple)
COMP 7.905 3.965 1.1798 1b
Cytochrome c, somatic CYCS 6.334 6.000 0.0817 1c
Dickkopf homolog 1 (Xenopus laevis) DKK1 10.739 0.074 9.286 1b
Major histocompatibility complex, class II, DQ beta 1 HLA-
DQB1
6.670 2.209 1.850 1c
Immunoglobulin lambda-like polypeptide 1 IGLL1 7.157 1.889 2.466 1a
Karyopherin alpha 2 (RAG cohort 1, importin alpha 1) KPNA2 3.197 13.764 7.706 1a
Keratin 17 KRT17 9.568 6.028 0.809 1a, 1b
Laminin, gamma 2 LAMC2 6.704 2.248 1.817 1a, 1b
met proto-oncogene (hepatocyte growth factor receptor) MET 4.570 0.691 6.140 1b
Mesothelin MSLN 10.732 4.173 2.637 1b
Mucin 4, tracheobronchial MUC4 9.188 4.673 1.371 1b
Nucleosome assembly protein 1-like 1 NAP1L1 17.180 4.148 7.973 1a
Nicotinamide N-methyltransferase NNMT 6.673 0.404 4.532 1b
NAD(P)H dehydrogenase, quinone 1 NQO1 18.806 5.452 8.090 1b
BH-protocadherin (brain–heart) PCDH7 6.557 0.017 5.913 1a
Pleckstrin homology-like domain, family A, member 1 PHLDA1 3.745 2.003 7.664 1c
Prion protein (p27-30) (Creutzfeld–Jakob disease, Gerstmann–
Strausler–Scheinker syndrome, fatal familial insomnia)
PRNP 9.961 0.053 8.668 1c
Protein tyrosine phosphatase type IVA, member 1 PTP4A1 4.340 1.574 7.620 1c
RAS protein activator like 2 RASAL2 6.947 3.974 0.751 1b
Solute carrier family 16 (monocarboxylic acid transporters),
member 3
SLC16A3 9.039 6.121 0.571 1b
Thioredoxin reductase 1 TXNRD1 7.973 0.391 5.672 1c
PDAC, pancreatic ductal adenocarcinoma. 1a (Gru ¨tzmann et al, 2004). 1b (Iacobuzio-Donahue et al, 2003b). 1c (Han et al, 2002).
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WNT-signalling pathway, which were significantly regulated in
primary tumour in comparison with the tumour invasion front
and the liver metastases. Comparing the primary tumour with the
tumour invasion front, we found other significantly regulated
pathways such as growth factor and common cytokines, which
play an important role in cell growth and differentiation (Table 2).
Not surprisingly, the pathway growth factor is significantly
regulated, as it is a marker pathway for a selective growth
advantage (Westphal and Kalthoff, 2003). Human pancreatic
cancer cells are reported to produce multiple growth factors like
insulin-like growth factor (IGF) and its receptors (IGF-1R and IGF-2
receptor), epidermal growth factor (EGF), transforming growth
factor-alpha (TGF-alpha), transforming growth factor-beta (TGF-beta),
fibroblast growth factor (FGF), vascular endothelial growth factors
(VEGFs) and their receptors (Westphal and Kalthoff, 2003).
Remarkably, for the link between the primary tumour and liver
metastases, apoptosis-related pathways like apoptosis-bcl2 and
map kinase active transcription factor are significantly regulated
(Table 2). Apoptosis and the MAP kinase are known to play a
pivotal role in pancreatic cancer (Westphal and Kalthoff, 2003).
Subsuming ORA is able to identify specific pathways correlating
with a specific biological behaviour.
Furthermore, we defined a panel of eight significantly regulated
genes showing high P-values and high log2 fold changes. These
were compared with the data in the current literature. This panel
consists of VEGF, NSE, HSP27, BNIP3L, PAI-1, GADD45A,
PTNPN14 and RGS4 (Table 1), and these genes are validated by
immunohistochemistry (shown exemplary in Figures 1–3).
Vascular endothelial growth factor is a marker of prognostic
relevance and a predictor for an early recurrence after curative
resection of ductal adenocarcinoma of the pancreas (Niedergethmann
et al, 2002). We found VEGF to be downregulated in liver
metastases (Table 1), underlining its key role in tumour-cell
migration and haematogenous spread in primary lesions. Similar
to our setting, Fukuhara et al (2005) showed that the VEGF
expression is initially reduced in liver metastases. We have already
demonstrated a correlation between the intensity of VEGF
expression in PDAC and the biological behaviour in terms of
early recurrence and poor survival after R0 resection in our earlier
work (Niedergethmann et al, 2002). Immunohistological staining
showed a high immunoreactivity with a score of 3 in primary
tumours, whereas in the liver metastases, VEGF expression rate
was lower with a score of 2. The tumour invasion front, however,
displayed a staining with a score of 2.8. The results of
immunohistochemistry are comparable to those of the array data.
A
B
Figure 1 (A, B) Immunohistochemistry of HSP27 showing equal
staining intensity in the primary lesion (A) and the liver metastasis (B), since
the gene expression was as well equal in the array ( 200 magnification).
A
B
Figure 2 (A, B) Immunohistochemistry of BNIP3L of the primary
tumour (A) and of the liver metastasis (B) with a weaker staining ( 200
magnification).
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immunoreactivity in the liver metastases in comparison with the
primary tumours reflect the pivotal role of angiogenesis in primary
lesions.
Neuron-specific enolase, the glycolytic isoenzyme of the enolase
gamma–gamma dimer, is a specific marker for the diffuse
neuroendocrine system and derivate tumours. It can be considered
as a reliable marker in the differential diagnosis between endocrine
and neuroendocrine neoplasias (D’Alessandro et al, 1992). Its
concentration is elevated in plasma in certain neoplasias including
paediatric neuroblastoma and small-cell lung cancer (Massaron
et al, 1998; Song et al, 2004). In anaplastic carcinoma of the
pancreas (Sawai et al, 2005) and in solid-cystic (papillary cystic)
tumour of the pancreas, the protein NSE is expressed (Chott et al,
1987). In the immunohistochemical staining, NSE showed stronger
staining (score 3) in primary tumour than in liver metastases
(score 2). The tumour invasion front revealed also a lower staining
in comparison with the primary tumour, with a score of 2.4,
analogous to the results from the array data (Table 4).
The heat shock 27-kDa protein 1 (HSP27) belongs to a larger
group of polypeptides, the stress proteins, and its reduced
expression, as in our setting, is an early marker of poor prognosis.
It is for instance useful in identifying aggressive biological
behaviour in oral squamous-cell carcinoma (Lo Muzio et al,
2006). Recently, HSP27 has been described as a potential marker
for pancreatic cancer (Melle et al, 2007). Considering the staining
results there is no difference between the primary tumour, the liver
metastases and the tumour invasion front. All tissues present a
staining with a score 42. Therefore, HSP27 is not specific enough
to reveal differences in the progression of pancreatic cancer.
BNIP3L is a member of the BCL-2 family, which are critical
regulators of apoptosis by either inhibiting or promoting cell
death. BNIP3L protein expression is downregulated in lung cancer
(Sun et al, 2004). Similar to lung cancer we found BNIP3L to be
downregulated in metastases and tumour invasion front in our
model, underlining its pivotal role in apoptosis. Han et al (2002)
have already described the expression of BNIP3l in PDAC. The
results of the staining revealed the highest staining score of 3 for
BNIP3l in the primary tumour. In addition there is a decrease in
immunoreactivity comparing the tumour invasion front (score 2.2)
with the liver metastases (score 1).
Plasminogen activator inhibitor 1 is a member of the serpine
family of serine protease inhibitors, and is one of the key
regulators of tumour invasion and metastases (Inoue et al, 2005;
Beyer et al, 2006). In oral squamous-cell carcinoma PAI-1 is a
novel potential marker of initial invasion (Lindberg et al, 2006). As
previously reported by our group (Niedergethmann et al, 2004),
similar to plasminogen and cathepsin B/C and their inhibitors, the
serine proteases are of paramount importance in local invasion
and metastases in PDAC. Takeuchi et al (1993) could already
demonstrate a high PAI-1 expression in human pancreatic
carcinomas in an immunohistochemical study. There are data
advocating that the uPA/uPAR/PAI-1 system is activated in
advanced pancreatic cancer and may account for the tumour’s
A
B
Figure 3 (A and B) Immunohistochemistry of PTPN14 with a strong
staining in the primary lesions (A) compared with a weak staining in the
liver metastasis reflecting equal array results ( 200 magnification).
Table 4 Panel of marker genes: expression values, which are standardised regarding to primary tumour and results of immunohistochemistry
Primary tumour Invasion front Liver metastases
Expression value
a IHCS Expression value
a IHCS Expression value
a IHCS
VEGF 1 3 0.449 2.8 0.516 2
PAI-1 1 3 0.526 2.4 0.928 2
RGS4 1 1 0.537 1.2 0.444 0
BNIP3l 1 3 0.516 2.2 0.411 1
GADD45A 1 1 0.586 1 0.499 1
HSP27 1 3 0.670 2.6 0.561 3
PTPN14 1 2.4 0.571 2.6 0.488 1
NSE 1 3 0.568 2.4 0.590 2
GADDA45A¼growth arrest and DNA damage-inducible gene 45; HSP27¼heat-shock 27-kDa protein 1; IHCS¼immunhistochemistry score; NSE¼neuron-specific enolase;
RGS4¼regulator of G protein signalling 4; VEGF¼vascular endothelial growth factor.
aExpression values are standardised regarding to primary tumour.
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expression of PAI-1 in the primary tumour, the tumour invasion
front and the metastases. The staining showed a slight decrease of
immunoreactivity when comparing the primary tumour (score 3)
with the tumour invasion front (score 2.4) and metastases
(score 2).
The growth arrest and DNA damage-inducible gene (GADD45A)
is a cell-cycle protein. It is an effective indicator of poor prognosis
in solid tumours such as lung cancer. In non-small cell lung
cancer, the downregulation of GADD45A is regarded as an
important key in the differentiation pathway (Higashi et al,
2006). Hollander et al (1999) could demonstrate that GADD45A is
a component of the p53 pathway, contributing to the maintenance
of genomic stability. Both p53 and GADD45A are highly expressed
in human pancreatic cancer and may be associated with pivotal
biological features of pancreatic cancer (Dong et al, 2005).
Downregulation of GADD45A, as in our setting, reduces prolifera-
tion and induces apoptosis in pancreatic cancer cells (Schneider
et al, 2006). GADD45A revealed a weak staining in all tissues with a
score of 1.
PTPN14 is a member of the protein tyrosine phosphatase family,
which is increased in many tumours, indicating that a complex
dysregulation in the balance of tyrosine phosphorylation could
be responsible for major alterations in various cellular processes
(Freiss and Vignon, 2004). Wang et al (2004) performed a
mutational analysis of the tyrosine phosphatase gene superfamily
in human cancers, and identified 83 somatic mutations in six
protein-tyrosine phosphatases one of which is PTPN14. PTPN14
demonstrated a high immunoreactivity score of 2.4 in the primary
tumour, whereas there was no decrease observed in the tumour
invasion front (score 2.4). In liver metastases we observed a score
of 1, confirming the hybridisation data described.
Regulator of G protein signalling 4 is regarded as a novel
inhibitor of tubulogenesis; it inhibits mitogen-activated protein
kinases and VEGF signalling (Albig and Schiemann, 2005). Due to
its downregulation in our model, one could speculate that its
inhibitory role is lost in PDAC. The immunohistochemical staining
was weak. In the primary tumour it showed a score of 1, in the
tumour invasion front a score of 1.2 and no immunoreactivity was
found in the liver metastases.
Using the SCID mouse model we could obtain a convincing
panel of genes associated with local invasion and metastases.
Beside current diagnostic work-up for PDAC, this gene and
pathway panel may deliver additional information about tumours,
which have already spread beyond surgical margins. This
implicates further validation in a series of human patient
specimen. Since resectability cannot be sufficiently predicted
using the conventional diagnostic measures, this additional
information might be helpful in planning the appropriate
treatment. On the other hand, local involvement of vessels and
surrounding organs is still a diagnostic problem. Having
additional staging details by possible biomarkers physicians can
be provided with information for planning the further procedure.
Furthermore, panels such as that of ours are of importance in
understanding the biological behaviour of PDAC.
In conclusion, microarray-based transcript analyses have
broadened our understanding of tumour biology. Based on
metastasising models such as the presented SCID mouse model,
biological behaviour can be studied and analysed. These data may
influence future diagnostic and therapeutic strategies for the
treatment of PDAC. With the rapid progress made in the handling
and analysis of microarrays, it can be assumed that more insight
will soon be gained into the fundamental changes occurring within
a cancer cell. In future, microarray technology will be broadly
introduced into clinical practice.
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